These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 1374791)

  • 41. Rapid phenotypic reversion of zidovudine-resistant feline immunodeficiency virus without loss of drug-resistant reverse transcriptase.
    Remington KM; Zhu YQ; Phillips TR; North TW
    J Virol; 1994 Feb; 68(2):632-7. PubMed ID: 7507182
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Natural resistance of human immunodeficiency virus type 2 to zidovudine.
    Reid P; MacInnes H; Cong ME; Heneine W; García-Lerma JG
    Virology; 2005 Jun; 336(2):251-64. PubMed ID: 15892966
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Biochemical and genetical analysis of AZT-resistant HIV-mutants.
    Biesert L; Zimmermann F; Schröder B; Matthes E; Suhartono H; Dietrich U; Rübsamen-Waigmann H
    Behring Inst Mitt; 1991 Jul; (89):74-80. PubMed ID: 1930105
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anti-HIV type 1 activity of 3'-fluoro-3'-deoxythymidine for several different multidrug-resistant mutants.
    Kim EY; Vrang L; Oberg B; Merigan TC
    AIDS Res Hum Retroviruses; 2001 Mar; 17(5):401-7. PubMed ID: 11282008
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Analysis of the Zidovudine Resistance Mutations T215Y, M41L, and L210W in HIV-1 Reverse Transcriptase.
    Boyer PL; Das K; Arnold E; Hughes SH
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7184-96. PubMed ID: 26324274
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo.
    Nijhuis M; Schuurman R; de Jong D; van Leeuwen R; Lange J; Danner S; Keulen W; de Groot T; Boucher CA
    J Infect Dis; 1997 Aug; 176(2):398-405. PubMed ID: 9237704
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Retroviral recombination can lead to linkage of reverse transcriptase mutations that confer increased zidovudine resistance.
    Kellam P; Larder BA
    J Virol; 1995 Feb; 69(2):669-74. PubMed ID: 7529334
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Transmission of zidovudine-resistant HIV-1 through heterosexual contacts.
    Angarano G; Monno L; Appice A; Giannelli A; Romanelli C; Fico C; Pastore G
    AIDS; 1994 Jul; 8(7):1013-4. PubMed ID: 7524541
    [No Abstract]   [Full Text] [Related]  

  • 49. Convergent evolution of reverse transcriptase (RT) genes of human immunodeficiency virus type 1 subtypes E and B following nucleoside analogue RT inhibitor therapies.
    Sato H; Tomita Y; Shibamura K; Shiino T; Miyakuni T; Takebe Y
    J Virol; 2000 Jun; 74(11):5357-62. PubMed ID: 10799614
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Biological testing versus sequence analysis for determination of drug resistance of human immunodeficiency virus.
    Wichers M; Kaiser R; Rockstroh J; Matz B; Schneweis KE
    Zentralbl Bakteriol; 1996 Jul; 284(2-3):457-65. PubMed ID: 8837404
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Concurrent evolution of regions of the envelope and polymerase genes of human immunodeficiency virus type 1 during zidovudine (AZT) therapy.
    Sheehy N; Desselberger U; Whitwell H; Ball JK
    J Gen Virol; 1996 May; 77 ( Pt 5)():1071-81. PubMed ID: 8609473
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication.
    Naeger LK; Margot NA; Miller MD
    Antivir Ther; 2001 Jun; 6(2):115-26. PubMed ID: 11491416
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine.
    Gao Q; Gu ZX; Parniak MA; Li XG; Wainberg MA
    J Virol; 1992 Jan; 66(1):12-9. PubMed ID: 1727474
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Why do HIV-1 and HIV-2 use different pathways to develop AZT resistance?
    Boyer PL; Sarafianos SG; Clark PK; Arnold E; Hughes SH
    PLoS Pathog; 2006 Feb; 2(2):e10. PubMed ID: 16485036
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Predominance of codon 215 mutation in reverse transcriptase-coding region of 3'-azido-3'-deoxythymidine (AZT)-resistant HIV-1 isolates after long-term AZT therapy.
    Kondo M
    Kansenshogaku Zasshi; 1995 Nov; 69(11):1278-85. PubMed ID: 8708409
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Stability of human immunodeficiency virus to azidothymidine. II. Kinetic characteristics of "AZT-resistant" mutant forms of reverse transcriptase].
    Pokholok DK; Gudima SO; Memelova LV; Esipov DS; Rechinskiĭ VO; Kochetkov SN
    Biokhimiia; 1996 Jan; 61(1):142-51. PubMed ID: 8679772
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Susceptibility of HIV-1 isolates to zidovudine: correlation between widely applicable culture test and PCR analysis.
    Jung M; Agut H; Candotti D; Ingrand D; Katlama C; Huraux JM
    J Acquir Immune Defic Syndr (1988); 1992; 5(4):359-64. PubMed ID: 1372352
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A microtitre format point mutation assay: application to the detection of drug resistance in human immunodeficiency virus type-1 infected patients treated with zidovudine.
    Kaye S; Loveday C; Tedder RS
    J Med Virol; 1992 Aug; 37(4):241-6. PubMed ID: 1383414
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Genotypic evolution of HIV-1 isolates from patients after a switch of therapy from zidovudine to didanosine.
    Masquelier B; Pellegrin I; Ruffault A; Ragnaud JM; Morlat P; Michelet C; Doignon F; Biteau N; Fleury HJ
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Apr; 8(4):330-4. PubMed ID: 7533640
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Biological and biochemical anti-human immunodeficiency virus activity of UC 38, a new non-nucleoside reverse transcriptase inhibitor.
    McMahon JB; Buckheit RW; Gulakowski RJ; Currens MJ; Vistica DT; Shoemaker RH; Stinson SF; Russell JD; Bader JP; Narayanan VL; Schultz RJ; Brouwer WG; Felauer EE; Boyd MR
    J Pharmacol Exp Ther; 1996 Jan; 276(1):298-305. PubMed ID: 8558446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.